Chardan

In October, the spotlight turns to Chicago: Benzinga’s Small-Cap Conference 2024 will gather top players in the small-cap investment world. Set for Oct. 9-10 at the Marriott Magnificent Mile, this event promises to be a focal point for those looking to understand and navigate the...

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutic areas. The Moderna Analysts: Chardan analyst Geulah Livshits has a Buy rating on Moderna with a $95 price target.  SVB Leerink analyst Mani...

After hinting at ongoing negotiations for larger vaccine deals on its earnings call, Moderna Inc (NASDAQ: MRNA) said late Tuesday that it signed an agreement with the U.S. government to supply 100 million doses of its coronavirus vaccine candidate mRNA-1273 for $1.525 billion. The Moderna...

Amid chatter that Moderna's Inc (NASDAQ: MRNA) investigational coronavirus vaccine is pricier relative to rivals, the company offered some clarity on pricing on its earnings call. An analyst at Chardan detailed COVID-19 vaccine pricing dynamics in a Thursday note.  The Moderna...

Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session.  Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board...

Adverum Biotechnologies Inc (NASDAQ: ADVM) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-related macular degeneration, or AMD. Efficacy, Safety Established Adverum said data from six patients in cohort...

The Medicines Company (NASDAQ: MDCO) stock has staged a nice recovery in the first half of 2019 after a steep 60% pullback in the second half of 2018 that dragged it to a 52-week low of $16.69 on Dec. 21. From the low, the stock rallied to an intraday peak of $38.96 on July 11, 2019, a 133%...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

Roche Holdings AG Basel ADR (OTC: RHHBY)'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) has sparked a rally in the latter's shares. The Analysts Chardan analyst Gbola Amusa maintained a Neutral on Spark and lifted the...

Tocagen Inc (NASDAQ: TOCA), which focuses on developing cancer-selective gene therapies based on a retroviral replicating vector platform, has earned a bullish review from Chardan. The Analyst Analyst Gbola Amusa initiated coverage of Tocagen with a Buy rating and $30 price target, suggesting...

Shares of virtual reality headset maker Vuzix Corp (NASDAQ: VUZI) are up strongly following the company's second-quarter report.  The Analyst Chardan analyst James McIlree maintained a Buy rating on Vuzix with a $10 price target.  The Thesis Q2 revenue of $2.6 million ...

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced a manufacturing-related hold Wednesday on its Phase 1/2 trial of microdystrophin gene therapy for Duchenne muscular dystrophy. Solid Biosciences Inc (NASDAQ: SLDB) fell in sympathy, but the competitor could benefit from Sarepta’s delay. The...

The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The Rating Chardan analyst Gbola Amusa maintained a Buy rating on the stock, but increased his price...

Shares of Crispr Therapeutics AG (NASDAQ: CRSP) fell more than 7 percent Thursday morning after the U.S. Food and Drug Administration said it placed a clinical hold on the company's therapy. What Happened The FDA placed a clinical hold on the Investigational New Drug application for Crispr...

Uniqure NV (NASDAQ: QURE) struck all-time highs last week and continued to linger near its peak value. One analyst projects 61-percent upside and considers the equity a top pick in 2018.  The Rating Chardan analyst Gbola Amusa maintained a Buy rating on uniQure and increased the price target...